Neurology > > General Neurology– Longtime NIA scientist examined synaptic damage in neurodegenerative conditions
by Judy George, Deputy Managing Editor, MedPage Today September 26, 2024
The NIH discovered proof of research study misbehavior by Eliezer Masliah, MD, a long time head of the neuroscience department of the National Institute on Aging (NIA), the company stated Thursday.
The falsification or fabrication included re-using and relabeling figure panels representing various speculative lead to 2 publications, the NIH stated, keeping in mind that it will inform the 2 journals of its findings so that suitable action can be taken.
Presently, Masliah is not acting as the NIA neuroscience director, with NIA Deputy Director Amy Kelley, MD, acting as the acting neuroscience director, the company specified.
NIH began its research study misbehavior evaluation procedure in May 2023 after it got accusations from the HHS Office of Research Integrity (ORI). The company started its examination stage in December 2023, concluded its probe on Sept. 15, 2024, and informed the HHS ORI of its findings.
In 2016, Masliah signed up with the NIA as its neuroscience chief and an NIH intramural scientist examining synaptic damage in neurodegenerative conditions. He released many documents as an NIH intramural scientist, according to the company.
“Any accusations including Dr. Masliah’s NIH-supported extramural research study prior to signing up with NIH would be described HHS ORI, constant with NIH policies and treatments,” the company stated.
The NIH statement accompanied the publication of a short article in Science questioning images in more than 100 documents that Masliah was included with. The images appeared to include transformed western blots, which are utilized to reveal the existence of proteins.
The Science short article recommended that Masliah’s operate in animal research study in 2005 might have assisted the FDA choose to authorize medical trials of prasinezumab, an investigational representative targeting alpha-synuclein in Parkinson’s illness.
Prasinezumab later on stopped working a stage II trial in people with Parkinson’s, however a stage IIb research study is presently underway. Exploratory analyses released in Nature Medicine and gone over at the 2024 American Academy of Neurology (AAN) yearly conference have actually recommended that the monoclonal antibody might slow motor development in specific subgroups of Parkinson’s clients.
Science Pointed out mouse research studies of cerebrolysin– a treatment authorized in other nations, however not the U.S.– that were performed at Masliah’s previous laboratory at the University of California San Diego, and research study including an investigational Parkinson’s drug understood as minzasolmin from a business Masliah co-founded in 2008.
Kept in mind Parkinson’s expert Michael Okun, MD, of the University of Florida in Gainesville, stated others ought to think about how the Science post can enhance the quality and trustworthiness of research study. “Let’s utilize this info to enhance the details we offer to researchers and society,” Okun published on X.
-
Judy George covers neurology and neuroscience news for MedPage Today, discussing brain aging, Alzheimer’s, dementia,